Fort Worth, TX, United States of America

Jami Kern

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Nacuity Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jami Kern. Retrieved from https://idiyas.com/inventor/jami-kern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jami Kern and a Patent Approach to Retinitis Pigmentosa

Introduction

Jami Kern is an inventor associated with Fort Worth, Texas, and Nacuity Pharmaceuticals, Inc. Her patent work addresses retinitis pigmentosa, including cases associated with Usher syndrome.

Latest Patents

Kern is named on 1 patent: “Treatment of Retinitis Pigmentosa and Retinitis Pigmentosa Associated with Usher Syndrome with N-Acetylcysteine Amide.” The patent describes methods for treating retinitis pigmentosa in humans by administering a therapeutically effective amount of N-acetylcysteine amide, also known as NACA.

Career Highlights

Kern’s listed work connects her with Nacuity Pharmaceuticals, Inc., a company focused on developing treatments. Her patent reflects research into the potential use of NACA for retinitis pigmentosa and related conditions.

Collaborations

Kern’s listed coworker is G. Michael Wall. The patent’s subject matter represents work in the broader effort to investigate therapeutic approaches for retinal disease.

Conclusion

Jami Kern’s patent contribution centers on the proposed use of NACA to treat retinitis pigmentosa, including disease associated with Usher syndrome.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…